Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

Plenary Session

Sunday, December 7, 2008: 2:00 PM-4:00 PM
Halls B and C (Moscone Center)
2:00 PM
A Prospective Randomized Study Comparing Rituximab and Dexamethasone Vs Dexamethasone Alone in ITP: Results of Final Analysis and Long Term Follow upClinically Relevant Abstract

Francesco Zaja1*, Michele Baccarani2, Patrizio Mazza3*, Nicola Vianelli4*, Monica Bocchia5*, Luigi Gugliotta, MD6, Marzia Defina7*, Alessia Tieghi6*, Sergio Amadori8, Selenia Campagna8*, Felicetto Ferrara9, Maria Carla De Simone10*, Alfonso Zaccaria11*, Anna Lia Molinari11*, Emanuele Angelucci12, Emilio Usala12*, Silvia Cantoni13*, Antonella Fornaro14*, Giuseppe Visani15*, Rita Rizzi16*, Valerio De Stefano17*, Francesco Casulli3*, Marta Lisa Battista1*, Miriam Isola18*, Franca Soldano18*, Mario Regazzi19*, Enrica Gamba20* and Renato Fanin1*

1Clinica Ematologica DIRM AOUD, Udine, Italy
2Department of Hematology/Oncology "L. and A. Seragnoli", University of Bologna, Italy
3Ematologia-Taranto, Italy
4Istituto L.A. Seràgnoli-Bologna, Italy
5Clinica Ematologica-Siena, Siena, Italy
6Ematologia-Reggio Emilia, Italy
7Clinica Ematologica-Siena, Italy
8Ematologia Tor Vergata-Roma, Italy
9Department of Hematology, Ospedale Cardarelli, Naples, Italy
10Ematologia Cardarelli-Napoli, Italy
11Ematologia-Ravenna, Italy
12Ematologia-Cagliari, Italy
13Ematologia Niguarda-Milano, Italy
14Ematologia-Pescara, Italy
15Ematologia-Pesaro, Italy
16Clinica Ematologica-Bari, Italy
17Ematologia Cattolica-Roma, Italy
18Istituto Statistica DIRM-Udine, Italy
19Istituto di Farmacologia-Pavia, Italy
20Roche-Monza, Italy

2:20 PM
Sequence of Genetic Events in ETV6-RUNX1 Positive B Precursor ALL: Insights from Identical Twins with Concordant Leukaemia

Caroline M Bateman, MBBS, MRCP1*, Sharon W Horsley1*, Tracy Chaplin2*, Bryan D Young2*, Anthony M Ford1, Lyndal Kearney1 and Mel Greaves1*

1Section of Haemato-Oncology, The Institute of Cancer Research, Sutton, Surrey, United Kingdom
2Medical Oncology Unit, Cancer Research UK, London

2:40 PM
Fostamatinib Disodium (FosD), An Oral Inhibitor of Syk, Is Well-Tolerated and Has Significant Clinical Activity in Diffuse Large B Cell Lymphoma (DLBCL) and Chronic Lymphocytic Leukemia (SLL/CLL)

Jonathan W. Friedberg, MD1, Jeff Sharman2*, Julia Schaefer-Cutillo1*, Patrick B. Johnston3*, Sven De Vos, MD, PhD4*, Ann LaCasce, MD5, John P. Leonard, MD6, Larry D. Cripe, MD7, Rajni Sinha, MD8*, Stephanie A. Gregory9*, John Sweetenham10*, Julie M. Vose, MD11, Ann M Lowe, MD12, R. Levy13 and Margaret A. Shipp, MD14

1James P. Wilmot Cancer Center, University of Rochester, Rochester, NY
2Stanford University
3Mayo Clinic Graduate School of Medicine, Rochester, MN
4David Geffen School of Med. at UCLA, Los Angeles, CA
5Dana-Farber Cancer Inst., Boston, MA
6Division of Hem./Onc., Weill Cornell Medical College, New York, NY
7Indiana University Simon Cancer Center, Indianapolis, IN
8Heme/Onc, Emory University
9Section of Hematology & Stem Cell Transplantation, Rush University Medical Center, Chicago, IL
10Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
11Univ. of NE Med. Ctr., Omaha, NE
12Rigel Pharmaceuticals, South San Francisco, CA
13Oncology, Stanford University, Stanford, CA
14Dana-Farber Cancer Institute, Boston, MA

3:00 PM
Mesenchymal Stem Cells, Regulated by the Sympathetic Nervous System, Form the Hematopoietic Stem Cell Niche

Simon Mendez-Ferrer, Ph.D.1*, Grigori N. Enikolopov, Ph.D.2*, Sergio Lira, M.D., Ph.D.3* and Paul S. Frenette, M.D.4

1Mount Sinai School of Medicine, New York, NY
2Cold Spring Harbor Laboratory, New York, NY
3Mount Sinai School of Medicine
4Department of Medicine and Immunology Institute, Mount Sinai School of Medicine, New York, NY

3:20 PM
A Novel Clinical Syndrome Associating Severe Congenital Neutropenia and Complex Developmental Aberrations Caused by Deficiency of G6PC3Clinically Relevant Abstract

Kaan Boztug1*, Giridharan Appaswamy1*, Angel Ashikov2*, Alejandro A Schäffer3*, Ulrich Salzer4*, Jana Diestelhorst1*, Manuela Germeshausen1*, Gudrun Brandes5*, Jacqueline Lee-Gossler5*, Fatih Noyan1*, Anna-Katherina Gatzke1*, Milen Minkov6*, Johann Greil7*, Christian Kratz8, Theoni Petropoulou9*, Isabelle Pellier10*, Christine Bellanne-Chantelot11*, Nima Rezaei12*, Kirsten Mönkemöller13*, Noha Irani-Hakimeh14*, Hans Bakker2*, Rita Gerardy-Schahn5*, Cornelia Zeidler1*, Bodo Grimbacher15*, Karl Welte1 and Christoph Klein16

1Department of Pediatric Hematology/Oncology, Hannover Medical School, Hannover, Germany
2Department of Cellular Chemistry, Hannover Medical School, Hannover, Germany
3National Center for Biotechnology Information, National Institutes of Health, Bethesda
4Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, Freiburg, Germany
5Department of Cell Biology, Hannover Medical School, Hannover, Germany
6Department of Pediatric Hematology/Oncology, St. Anna Children's Hospital, Vienna, Austria
7Department of Pediatric Oncology, Hematology and Immunology, Children's Hospital, University of Heidelberg, Heidelberg, Germany
8Department of Pediatric Hematology/Oncology, University of Freiburg, Freiburg, Germany
9Aghia Sophia Children's Hospital, Athens
10Unité Immuno-Hémato-Oncologie Pédiatrique, CHU Angers, Angers, France
11Department of Genetics, AP-HP Pitié-Salpétriére, Paris, France
12Immunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, Tehran, Iran
13Department of General Pediatrics, Children's Hospital Amsterdamer Straße, Cologne, Germany
14Department of Laboratory Medicine and Blood Bank, Saint George University Hospital, Beirut, Lebanon
15Department of Immunology, Royal Free Hospital and University College London, London, United Kingdom
16Department of Pediatric Hematology/Oncology, Medical School Hannover, Hannover, Germany

3:40 PM
A Randomized Double-Blind Placebo-Controlled Study on Nadroparin for Prophylaxis of Thromboembolic Events in Cancer Patients Receiving Chemotherapy: The PROTECHT StudyClinically Relevant Abstract

Giancarlo Agnelli, M.D.1*, Gualberto Gussoni, M.D.2*, Carlo Bianchini, M.D.3*, Melina Verso, M.D.1* and Maurizio Tonato, M.D.4*

1Internal and Cardiovascular Medicine, University of Perugia, Perugia, Italy
2Protecht Clinical Project Leader, Milan, Italy
3Scientific Department, Italfarmaco, Milan, Italy
4Regional Cancer Center, Perugia, Italy

*signifies non-member of ASH